CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


serum inflammatory biomarkersWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1672 Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 COVID-19 Inflammatory Blood Biomarkers for Clinical Management, Prognosis and Evaluation of Interventions

Emergent experimental and anecdotal evidence has indicated that critically ill COVID-19 patients demonstrate two patient sub-types (called phenotypes). In one group the disease progresses slowly and patients have a low potential of developing mild respiratory failure, but in the other group, an exaggerated immune response (hyper-inflammation/cytokine storm) may be linked to the onset of precipitous respiratory failure, termed acute respiratory distress syndrome. This syndrome is responsible for a large portion of COVID-19 associated mortality. Thus, determining links between hyper-inflammation and acute respiratory distress syndrome in COVID-19 patients is of immediate importance. Blood samples will undergo a number of analyses to help us to understand as much as possible about COVID-19. We will also study any differences in physiologic and cytokine levels before and after patients are treated with immunomodulatory therapies as part of clinical care in COVID-19 patients.

NCT04363008 COVID 19 Diagnostic Test: serum inflammatory biomarkers

Primary Outcomes

Description: Interleukin 1b, 6, 10 and tumor necrosis factor alpha

Measure: Inflammation

Time: 24 hours

Description: Ratio of arterial oxygen tension (mmHg) to fraction of inspired oxygen (PaO2/FiO2)

Measure: Oxygenation

Time: 24 hours

Secondary Outcomes

Description: Pulmonary function tests (forced vital capacity (ml))

Measure: Chronic Pulmonary outcomes

Time: 8 to 12 weeks after discharge

Description: Pulmonary artery pressure (mmHg)

Measure: Pulmonary artery pressure using transthoracic echocardiography

Time: 8 to 12 weeks after discharge

Description: 6-minute walk test

Measure: Exertion

Time: 8 to 12 weeks after discharge

Description: Short Form 36 (range 0 - 100)

Measure: Quality of life assessment

Time: 8 to 12 weeks after discharge

Other Outcomes

Description: Ventilator free days

Measure: Duration of mechanical ventilation

Time: 30 days


No related HPO nodes (Using clinical trials)